SGLT2 inhibitor for calcium and magnesium in ADPKD
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help control calcium and magnesium levels in people with a genetic kidney disease called ADPKD. The goal is to see if it improves kidney health over a short period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of autosomal dominant polycystic kidney disease (ADPKD).
- You cannot be on dialysis or have had a kidney transplant.
- Your kidney function (eGFR) must be at least 30 mL/min/1.73 m² (not stage 4 or worse).
- You must not have type 1 diabetes, uncontrolled high blood pressure, or serious liver disease.
- You must be willing to stop certain medications (like thiazide diuretics and vitamin D) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This Phase 3 study tests whether taking metformin can slow the decline of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). You may be eligible if you have ADPKD and signs that your kidneys are starting to decline faster than expected.
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
This study looks at how SGLT2 inhibitors (a type of diabetes medication) protect the kidneys in people with type 2 diabetes and kidney disease. It may help explain why these drugs are beneficial for kidney health.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
Hear when a new Autosomal Dominant Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.